OBJECTIVE: To assess the accuracy of an automated blood pressure device (Microlife 3BTO-A) in pregnancy and pre-eclampsia according to the British Hypertension Society (BHS) protocol. DESIGN: Prospective observational study. SETTING: Antenatal ward and clinics at Guy's and St Thomas' Hospital, London, UK. POPULATION: One hundred and five pregnant women including 35 women with non-proteinuric hypertension and 35 with pre-eclampsia. METHODS: Two trained observers took nine sequential same-arm measurements from each woman. Measurements alternated between a mercury sphygmomanometer and the device. MAIN OUTCOME MEASURES: Grading criteria of the BHS protocol (A/B grade = pass; C/D grade = fail). RESULTS: The device passed the BHS protocol by achieving an A/B grade. It also achieved criteria of the Association for the Advancement of Medical Instrumentation for systolic and diastolic pressures respectively, in normotensive [-0.5 (5.7) mmHg; -0.07 (7.7) mmHg], non-proteinuric hypertensive [-3.3 (6.9) mmHg; -2.4 (6.6) mmHg] and pre-eclamptic pregnancy [-4.1 (6.4) mmHg; -1.3 (7.9) mmHg]. CONCLUSION: The Microlife 3BTO-A can be recommended for use in a pregnant population, including pre-eclampsia, according to the BHS protocol.
OBJECTIVE: To assess the accuracy of an automated blood pressure device (Microlife 3BTO-A) in pregnancy and pre-eclampsia according to the British Hypertension Society (BHS) protocol. DESIGN: Prospective observational study. SETTING: Antenatal ward and clinics at Guy's and St Thomas' Hospital, London, UK. POPULATION: One hundred and five pregnant women including 35 women with non-proteinuric hypertension and 35 with pre-eclampsia. METHODS: Two trained observers took nine sequential same-arm measurements from each woman. Measurements alternated between a mercury sphygmomanometer and the device. MAIN OUTCOME MEASURES: Grading criteria of the BHS protocol (A/B grade = pass; C/D grade = fail). RESULTS: The device passed the BHS protocol by achieving an A/B grade. It also achieved criteria of the Association for the Advancement of Medical Instrumentation for systolic and diastolic pressures respectively, in normotensive [-0.5 (5.7) mmHg; -0.07 (7.7) mmHg], non-proteinuric hypertensive [-3.3 (6.9) mmHg; -2.4 (6.6) mmHg] and pre-eclamptic pregnancy [-4.1 (6.4) mmHg; -1.3 (7.9) mmHg]. CONCLUSION: The Microlife 3BTO-A can be recommended for use in a pregnant population, including pre-eclampsia, according to the BHS protocol.
Authors: Natalie A Bello; Jonathan J Woolley; Kirsten Lawrence Cleary; Louise Falzon; Bruce S Alpert; Suzanne Oparil; Gary Cutter; Ronald Wapner; Paul Muntner; Alan T Tita; Daichi Shimbo Journal: Hypertension Date: 2017-12-11 Impact factor: 10.190
Authors: Laura A Magee; Edgardo Abalos; Peter von Dadelszen; Baha Sibai; Tom Easterling; Steve Walkinshaw Journal: Br J Clin Pharmacol Date: 2011-09 Impact factor: 4.335
Authors: Natalie A Bello; Eliza Miller; Kirsten Cleary; Ronald Wapner; Daichi Shimbo; Alan T Tita Journal: Curr Hypertens Rep Date: 2018-10-25 Impact factor: 5.369
Authors: Marianne Vestgaard; Björg Ásbjörnsdóttir; Lene Ringholm; Lise Lotte T Andersen; Dorte M Jensen; Peter Damm; Elisabeth R Mathiesen Journal: Diabetologia Date: 2019-10-18 Impact factor: 10.122
Authors: Lise Loerup; Rebecca M Pullon; Jacqueline Birks; Susannah Fleming; Lucy H Mackillop; Stephen Gerry; Peter J Watkinson Journal: BMC Med Date: 2019-09-11 Impact factor: 8.775